teva pharmaceuticals introduces the first generic glp-1 for weight loss Diabetes patients now have access to medication: ‘More accessible and affordable’ Teva introduces generic Saxenda |
Description
In a separate analysis, lixisenatide reduced incident macroalbuminuria, while adjustments for baseline characteristics such as age, blood pressure and eGFR, as well as on trial HbA1c, blood pressure and weight, did not significantly attenuate the association [28]
The advantages: lower cost, more precise dose flexibility (you control exactly how much you draw), and generally better availability
The way through is to assign each measure an explicit job before the trial starts rather than after the results arrive
The company has been involved in several lawsuits regarding digital accessibility, unsolicited marketing text messages, and copyright infringement
The starting dose still serves its adaptation purpose regardless of body weight
Knowing this timeline helps contextualize the starting dose
